Accelerated atherosclerosis in systemic lupus erythematosus and other connective tissue diaseases

Expert Review of Clinical Immunology

Volumn 3, Issue 4, 2007, Pages 531-541

  Bocci, Elena Bartoloni ^a   Luccioli, Filippo ^a   Angrisani, Claudio ^a   Moscatelli, Sheila ^a   Alunno, Alessia ^a   Gerli, Roberto ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARYLDIALKYLPHOSPHATASE; C REACTIVE PROTEIN; CD40 LIGAND; CORTICOSTEROID; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPID ANTIBODY; PREDNISONE; SIMVASTATIN;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG INHIBITION; DYSLIPIDEMIA; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID PEROXIDATION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; OBESITY; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; RHEUMATIC DISEASE; SITTING; SJOEGREN SYNDROME; SMOKING; SMOKING CESSATION; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34447650249     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.4.531     Document Type: Review

References (88)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzio MA. The bimodal pattern of systemic lupus erythematosus. Am. J. Med. 60, 221-225 (1976).
2. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am. J. Epidemiol. 145,408-415 (1997).
3. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 42, 338-346(1999).
4. Esdaile JM, Abrahamowicz M, Grodzicky T et al. Traditional Framingham risk factors fail to account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 44, 2331-2337 (2001).
5. Hall FC, Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology 44, 1473-1482(2005).
6. Rhew EY, Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus - role of inflammatory mechanism. Autoimmunity Rev. 5, 101-105 (2006).
7. Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology 38, 529-534 (1999).
8. Morgan PE, Sturgess AD, Davies MJ. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum. 52, 2069-2079 (2005).
9. Frostegard J, Svenungson E, Wu R et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum. 52, 192-200(2005).
10. Tso T, Huang W, Huang HY, Chang CK. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology 45, 1148-1153 (2006).
11. Memon RA, Staprans I, Noor M et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler. Thromb. Vasc. Biol. 20, 1536-1542 (2000).
12. Matsuura E, Kobayashi K, Koike T, Shoenfeld Y. Autoantibody-mediated atherosclerosis. Autoimmunity Rev. 1, 348-353 (2002).
13. Kobayashi K, Kishi M, Atsumi T et al. Circulating oxidized LDL forms complexes with β2-glycoprotein I: implication as an atherogenic autoantigen. J. Lipid Res. 44, 716-726 (2003).
14. Liu Q, Kobayashi K, Furukawa J et al. ω-carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages. J. Lipid Res. 43,1486-1495(2002).
15. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR. Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid Res. 45, 466-486(2006).
16. Matsuura E, Kobayashi K, Hurley BL, Lopez LR. Atherogenic oxidized low-density lipoprotein/β2-glycoprotein I (oxLDL/β2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 15, 478-483 (2006).
17. Lopez LR, Simpson DF, Hurley BL, Matsuura E. OxLDL/β2GPI complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid sindrome: pathogenic implications for vascular involvement. Ann. NY Acad. Sci. 1051, 313-322 (2005).
18. Farzaneh-Far A, Roman MJ, Lockshin MD et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 54, 3918-3925 (2006).
19. Amoroso A, Cacciapaglia F, De Castro S et al. The adjunctive role of antiphospholipid antibodies in systemic lupus erythematosus cardiac involvement. Clin. Exp. Rheumatol. 24, 287-294 (2006).
20. Shoenfeld Y, Wu R, Dearing L, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective?. Circulation 110, 2552-2558 (2004).
21. Sherer Y, Shoenfeld Y. Mechanism of disease: atherosclerosis in autoimmune diseases. Nat. Clin. Pract. Rheumatol. 2, 99-106 (2006).
22. Asanuma Y, Chung CP, Oeser A et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J. Rheumatol. 33,539-545(2006).
23. 1 and early atherosclerosis in systemic lupus erythematosus. Arthritis Res. Ther. 8, R81 (2006).
24. McMahon M, Grossman J, FitzGerald J et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 54, 2541-2549 (2006).
25. Kiss E, Soltesz P, Der H et al. Reduced flow-mediated vasodilatation as a marker for cardiovascular complications in lupus patients. J. Autoimmunity 27, 211-217 (2006).
26. Wright SA, O'Prey FM, Rea DJ et al. Microcirculatory hemodynamics and endothelial dysfunction in systemic lupus erythematosus. Arterioscler. Thromb. Vasc. Biol. 26, 2281-2287 (2006).
27. Svenungsson E, Jensen-Urstad K, Heimbürger M et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887-1893 (2001).
28. - T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation 109,2744-2278(2004).
29. Sherer Y, Gerli R, Gliburd B et al. Thickened carotid artery intima-media in rheumatoid arthritis is associated with elevated anticardiolipin antibodies. Lupus 16, 259-264 (2007).
30. Gerli R, Sherer Y, Bartoloni Bocci E, Vaudo G, Moscatelli S, Shoenfeld Y. Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors. Ann. NY Acad. Sci. (2007) (In press).
31. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37, 1075-1082 (2001).
32. Selzer F, Sutton-Tyrrell K, Fitzgerald S et al. Comparison of risk factors for vascular disease in the carotid artery and aorta in women with systemic lupus erythernatosus. Arthritis Rheum. 50, 151-159 (2004).
33. Asanuma Y, Oeser A Shintani A et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2407-2415 (2003).
34. Von Feldt J, Scalzi L, Cucchiara A et al. Homocysteine levels and disease duration independently correlate with coronary artery calcifications in patients with systemic lupus erythematosus. Arthritis Rheum. 54, 2220-2227 (2006).
35. Frostegård J. Atherosclerosis in patients with autoimmune disorders. Arterioscler. Thromb. Vasc. Biol. 25, 1776-1785 (2005).
36. Bruce IN. "Not only...but also" factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology 44, 1492-1502 (2005).
37. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins lupus cohort: prevalence recognition by patients and preventive practise. Medicine 71, 291-302 (1992).
38. Bessant R, Duncan R, Ambler G, Swanton J, Isenberg D, Rahman A. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: a case - control study. Arthritis Care Res. 55, 892-899 (2006).
39. Toloza SM, Uribe AG, McGwin G et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). Baseline predictors of vascular events. Arthritis Rheum. 50, 3947-3957 (2004).
40. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 43, 924-929 (2004).
41. Doria A, Shoenfeld Y, Wu R et al. Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62, 1071-1077 (2003).
42. Roman MJ, Shanker B, Davis A et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N. Engl. J. Med. 349, 2399-2406 (2003).
43. Sarkissian T, Beyene J, Feldman B, McCrindle B, Silverman E. Longitudinal examination of lipid profiles in pediatric systemic lupus erythematosus. Arthritis Rheum. 56, 631-638 (2007).
44. Escàrcega R, Garcìa-Carrasco M, Fuentes-Alexandro S et al. Insulin resistance, chronic inflammatory state and the link with systemic lupus erythematosus-related coronary disease. Autoimmunity Rev. 6, 48-53 (2006).
45. El-Magadmi M, Ahmad Y, Turkic W et al. Hyperinsulinaemia, insulin resistance and circulating oxidised low density lipoprotein in women with systemic lupus erythematosus. J. Rheumatol 33, 50-56 (2006).
46. Chung CP Avalos I, Oeser A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristics and cardiovascular risk factors. Ann. Rheum. Dis. 66, 208-214 (2007).
47. Maksimowicz-McKinnon K, Madger L, Petri M. Predictors of carotid atherosclerosis in systemic lupus erythematosus. J. Rheumatol. 33, 2458-2463 (2006).
48. Manger K, Kusus M, Forster C et al. Factors associated with coronary artery calcification in young female patients with SLE. Ann. Rheum. Dis. 62, 846-850 (2003).
49. Hansson GK, Libby P, Schonbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ. Res. 91, 281-291 (2002).
50. Viedt C, Hansch GM, Brandes RP, Kubler W, Kreuzer J. The terminal complement complex C5b-C9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-κ B and AP-1. FASEB J. 14, 2370-2372 (2000).
51. Grainger D, Bethell HW. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Ann Rheum. Dis. 61, 110-114 (2002).
52. Marasini B, De Monti M, Ghilardi G. Risk factors for accelerated atherosclerosis in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 64, 163-164 (2005).
53. Yazdany J, Davis J. The role of CD40 ligand in systemic lupus erythematosus. Lupus 13, 377-380 (2004).
54. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann. Pharmacother 38, 1500-1508 (2004).
55. Nickolas TL, Radhakrishnan J, Appel GB. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy. Semin. Nephrol. 23, 406-411 (2003).
56. Borba EF, Bonfa E. Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J Rheumatol. 28, 780-785 (2001).
57. Prowse C, Pepper D, Dawes J. Prevention of the platelet α-granule release reaction by membrane-active drugs. Thromb. Res. 25, 219-227(1982).
58. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN, Ghara AE. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemostasis 87, 518-522 (2002).
59. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 109S, III27-III32 (2004).
60. Davignon J, Jacob RF, Mason RP. The antioxidant effect of statins. Coron. Artery Dis. 15, 251-258 (2004).
61. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 473-480 (2001).
62. Delgado-Alves J, Ames PR, Donohue S et al. Antibodies to high-density lipoprotein and β2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 46, 2686-2694 (2002).
63. Balogh Z, Seres I, Harangi M, Kovacs P, Kakuk G, Paragh G. Gemfibrozil increases paraoxonase activity in Type 2 diabetic patients: a new hypothesis of the beneficial action of fibrates? Diabetes Metab. 27, 604-610 (2001).
64. Kotyla P, Sliwinska-Kotyla B, Kucharz E. Tumor necrosis factor-α as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol. 33, 2361 (2005).
65. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mitura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor α in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol. 33, 463-471 (2006).
66. Matucci-Cerinic M, Fiori G, Grenbaum E, Shoenfeld Y. Macrovascular disease in systemic sclerosis. In: Systemic Sclerosis. Furst D, Clements P (Eds), Lippincott Williams and Wilkins, MD, USA 241 (2003).
67. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 112, 3337-3347 (2005).
68. Szücs G, Timàr O, Szekanecz Z et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis-relevance for prevention of vascular complications. Rheumatology 46, 759-762 (2007).
69. Borba EF, Borges CT, Bonfa E. Lipoprotein profile in limited systemic sclerosis. Rheumatol. Int. 25, 379-393 (2005).
70. Medina G, Casaos D, Jara L et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann, Rheum. Dis. 62, 607-610 (2003).
71. Ames PR, Delgado Alves J, Lopez LR et al. Antibodies against β2-glycoprotein I complexed with an oxidised lipoprotein relate to intima-media thickening of carotid arteries in primary antiphospholipid syndrome. Clin. Dev. Immunol. 13, 1-9 (2006).
72. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine levels independently predict intima-media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 11, 208-214 (2002).
73. Hojnik M, Gorge J, Ziporen L, Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 93, 1579-1587 (1996).
74. Turiel M, Muzzupappa G, Gottardi B, Crema C, Sarzi-Puttini P, Rossi E. Evaluation of cardiac abnormality and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 9, 406-412 (2000).
75. Vaudo G, Bartoloni Bocci E, Shoenfeld Y et al. Precocious intima-media thickening in patients with primary Sjögren's syndrome. Arthritis Rheum. 52, 3890-3897 (2005).
76. Gerli R, Muscat C, Giansanti M et al. Quantitative assessment of salivary gland inflammatory infiltration in primary Sjögren's syndrome: its relationship to different demographic, clinical and serological features of the disorder. Br. J. Rheumatol. 36, 969-975 (1997).
77. Lodde BM, Sankar V, Kok MR et al. Serum lipid levels in Sjögren's syndrome. Rheumatology 45, 481-484 (2006).
78. Gerli R, Bartoloni Bocci E, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjögren's syndrome-role of dyslipidaemia. Rheumatology 45, 1581-1582 (2006).
79. Lopez LR, Salazar-Paramo M, Patafox-Sanchez C et al. Oxidized low-density lipoprotein and β2-glycoprotein I in patients with systemic lupus erythematosus and increased carotid intima-media thickness: implications in autoimmune-mediated atherosclerosis. Lupus 15, 80-86 (2006).
80. Roman MJ, Salmon ES, Sabel R et al. Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome. Am. J. Cardiol. 87, 663-666 (2001).
81. Lima DS, Sato EI, Lima VC, Mirando F Jr, Hatta FH. Brachial endothelial function is impaired in patients with systemic lupus erythematosus.J Rheumatol. 29, 292-297 (2002).
82. Wolak T, Todosoui E, Szendro G et al. Duplex study of the carotid and femoral arteries of patients with systemic lupus erythematosus: a controlled study. J. Rheumatol. 31, 909-914 (2004).
83. Jiménez S, Garcìa-Criado M, Tàssies D et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology 44, 756-761 (2005).
84. El-Magadmi M, Bodill H, Ahmad Y et al. Systemic lupus erythematosus. An independent risk factor for endothelial dysfunction in women. Circulation 110, 399-404 (2004).
85. De Leeuw K, Freire B, Smit AJ, Bootsma H, Kallenberg CG, Bijl M. Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 15, 675-682 (2006).
86. Bhatt SP, Handa R, Gulati G et al. Atherosclerosis in Asian Indians with systemic lupus erythematosus. Scand. J. Rheumatol. 35, 128-132 (2006).
87. Sella E, Sato E, Leite W, Oliveira Filho J, Barbieri A. Myocardial perfusion scintigraphy and coronary disease risk factor in systemic lupus erythematosus. Ann. Rheum. Dis. 62, 1066-1070 (2003).
88. Bessant R, Hingorani A, Patel L, MacGregor A, Isenberg DA, Rahman A. Risk of coronary heart disease and stroke in a large British cohort of patients with systemic lupus erythematosus. Rheumatology 43, 924-929 (2004).